ArticleBritish journal of haematology2026
Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.
Wei Yee Chan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.